free-drug occupancy method (albumin Kd 1.86 uM, free fraction 0.29%): Willard JCI Insight 2020
BeOne Medicines BGB-16673, a novel treatment for chronic lymphocytic leukemia/small lymphocytic leukemia, with $1.2 billion in sales projected in 2031
You can typically resume GLP-1 therapy once you're tolerating a normal diet without nausea or vomiting, normal bowel function has returned, and your surgical team approves
If a dose is missed, it should be administered as soon as the patient remembers
Lean-mass loss is largely modifiable: adequate protein intake, progressive resistance training, and avoiding an overly aggressive deficit are the three levers that shift the ratio toward fat
On an empty GLP-1 stomach, this often triggers nausea and heartburn